Roche Products Limited

Hexagon Place, 6 Falcon Way, Shire Park, Welwyn Garden City, Hertfordshire, AL7 1TW
Telephone: +44 (0)1707 366 000
Fax: +44 (0)1707 338 297
WWW: http://www.rocheuk.com
Medical Information Direct Line: +44 (0)800 328 1629
Medical Information e-mail: medinfo.uk@roche.com
Customer Care direct line: +44 (0)800 731 5711
Medical Information Fax: +44 (0)1707 384555

Patient Information Leaflet last updated on the eMC: 23/12/2011
PIL MabThera 100mg and 500mg concentrate for solution for infusion

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 23/12/2011 and displayed until Current
Reasons for adding or updating:
  • Change to date of revision
  • Change to side-effects
Updated on 21/09/2011 and displayed until 23/12/2011
Reasons for adding or updating:
  • Change to side-effects
Updated on 08/11/2010 and displayed until 21/09/2011
Reasons for adding or updating:
  • Change to side-effects
Updated on 31/03/2010 and displayed until 08/11/2010
Reasons for adding or updating:
  • Change to side-effects
Updated on 16/09/2009 and displayed until 31/03/2010
Reasons for adding or updating:
  • Change to side-effects
Updated on 02/09/2009 and displayed until 16/09/2009
Reasons for adding or updating:
  • Change to side-effects
Updated on 26/02/2009 and displayed until 02/09/2009
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to side-effects
Updated on 12/12/2008 and displayed until 26/02/2009
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to side-effects
Updated on 23/07/2008 and displayed until 12/12/2008
Reasons for adding or updating:
  • Change to how the medicine works
  • Change to storage instructions
Updated on 01/07/2008 and displayed until 23/07/2008
Reasons for adding or updating:
  • Change of contra-indications
Updated on 31/01/2008 and displayed until 01/07/2008
Reasons for adding or updating:
  • New PIL for eMC ie a PIL for an existing product but one that is new to the eMC

Active Ingredients/Generics

 
   rituximab